Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Fewer than 1 in 10 were taking SGLT2 inhibitors. GLP-1 RAs are a new class of anti-hyperglycemic drugs shown to be beneficial in reducing albuminuria in patients with diabetes, independent of ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death and an 84% lower risk of heart attack compared to patients who did not take either medication. The death rate ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Although sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists show promise in reducing cardiovascular and kidney risks, the potential for GLP-1 receptor agonists to ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

How brands will alert consumers to their products' compatibility with GLP-1 drugs like Ozempic. Conagra Brands launches first ...

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...